Woodline Partners LP Has $50 Million Stake in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Woodline Partners LP increased its holdings in NewAmsterdam Pharma Company N.V. by 0.5%, now owning approximately 2.22% of the company, valued at about $50 million.
• Several institutional investors, including Adage Capital Partners GP and Wellington Management Group, made significant purchases during the 1st quarter, contributing to a total institutional ownership of 89.89%.
• NewAmsterdam Pharma's recent earnings report revealed a surprise profit, with a reported earnings per share of ($0.15), exceeding estimates and reflecting strong quarterly revenue growth.

Woodline Partners LP lifted its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 0.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,442,397 shares of the company's stock after purchasing an additional 11,615 shares during the period. Woodline Partners LP owned 2.22% of NewAmsterdam Pharma worth $49,996,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Frazier Life Sciences Management L.P. lifted its position in NewAmsterdam Pharma by 1.3% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 16,116,418 shares of the company's stock worth $329,903,000 after acquiring an additional 200,000 shares during the last quarter. RA Capital Management L.P. increased its stake in NewAmsterdam Pharma by 14.6% in the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock valued at $207,544,000 after acquiring an additional 1,293,938 shares during the period. Wellington Management Group LLP grew its stake in NewAmsterdam Pharma by 53.0% during the first quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company's stock worth $72,504,000 after buying an additional 1,226,852 shares during the last quarter. Alliancebernstein L.P. grew its stake in NewAmsterdam Pharma by 20.7% during the first quarter. Alliancebernstein L.P. now owns 2,241,953 shares of the company's stock worth $45,893,000 after buying an additional 383,888 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of NewAmsterdam Pharma by 85.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,950,650 shares of the company's stock valued at $39,930,000 after purchasing an additional 900,650 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Insider Activity at NewAmsterdam Pharma

In other news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the firm's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the completion of the sale, the insider owned 119,302 shares in the company, valued at approximately $2,897,845.58. This trade represents a 29.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James N. Topper bought 1,260 shares of the business's stock in a transaction dated Monday, September 8th. The shares were bought at an average price of $24.99 per share, with a total value of $31,487.40. Following the purchase, the director owned 3,027,864 shares in the company, valued at $75,666,321.36. The trade was a 0.04% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 14,095 shares of company stock worth $279,621 and have sold 424,954 shares worth $9,773,906. 20.84% of the stock is owned by insiders.

NewAmsterdam Pharma Trading Down 9.1%

Shares of NAMS traded down $2.41 during midday trading on Friday, reaching $24.19. The stock had a trading volume of 1,184,082 shares, compared to its average volume of 960,381. The firm has a 50 day simple moving average of $23.67 and a 200-day simple moving average of $20.82. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $27.35. The firm has a market cap of $2.72 billion, a PE ratio of -14.93 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. As a group, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Citigroup initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price objective on the stock. Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma in a research report on Monday, August 25th. They issued an "overweight" rating and a $45.00 target price for the company. Finally, The Goldman Sachs Group started coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $41.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.